The funds will be dispersed throughout the study’s five-year length.
The study aims to find the causes of Crohn’s disease and will analyze clinical, imaging, and endoscopic outcomes of children newly diagnosed with the condition. It will utilize 27 pediatric centers across North America to examine the response and remission after the treatment of anti-TNF biologics in children ages 6 to 17. Researchers hope to enroll 900 kids in the study, targeting 550 of them for specific treatments.
Dr. Hyams, who will lead the study, will be working alongside physicians from Cincinnati (Ohio) Children’s Hospital and Medical Center and Atlanta-based Emory University.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
